It’s not too late for flu vaccination

It’s not too late for flu vaccination — and this season the "Super Flu is going around.
Medscape recently interviewed Lisa Grohskopf, MD, MPH, from the CDC’s Influenza Division, who outlined two major changes for the 2024–2025 influenza season:

🔹 All U.S. flu vaccines are now trivalent, targeting A(H1N1), A(H3N2), and B/Victoria. The B/Yamagata component has been removed, as it disappeared from global circulation in 2020.
🔹 ACIP now recommends high‑dose or adjuvanted inactivated vaccines as acceptable options for adult solid organ transplant recipients (18–64), reflecting evidence of stronger immunogenicity in this population.

Dr. Grohskopf also reinforced that everyone aged ≥6 months should receive an annual flu vaccine, with special emphasis on adults ≥65, young children, and individuals with chronic conditions. And importantly: vaccination remains valuable well beyond October. Protection develops in about two weeks, and flu activity typically peaks in December, January, or later.

Coverage still hasn’t returned to pre‑COVID levels — a reminder that strong provider recommendations matter. The CDC’s SHARE framework remains a powerful tool for guiding patient conversations.

---

For diagnostics leaders navigating this season’s respiratory landscape:

The GRN IVD Consulting Point‑of‑Care Market Report delivers a clear, data‑driven view of platform performance, competitive positioning, and market dynamics across influenza and broader respiratory testing. If you support strategic decisions in POC diagnostics, this report is built for you.